Novo Seeks To Toss Antitrust Claims in Prandin Suit

Law360, New York (January 11, 2011, 4:29 PM EST) -- Pharmaceutical company Novo Nordisk Inc. has asked a judge to toss antitrust claims made by generic-drug maker Paddock Laboratories Inc. in an infringement dispute over Novo's diabetes drug Prandin, saying it is not to blame for Paddock's delayed market entry.

Novo Nordisk's motion, filed Monday in the U.S. District Court for the District of Minnesota, requests the dismissal of Paddock Laboratories Inc.'s three antitrust counterclaims because they fail to show that Novo acted to unlawfully monopolize the market for Prandin.

Paddock had argued that Novo prevented...
To view the full article, register now.